These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24166472)

  • 1. KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis.
    Huang C; Shen S; Ma Q; Gill A; Pollock CA; Chen XM
    Nephrol Dial Transplant; 2014 Feb; 29(2):313-24. PubMed ID: 24166472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic mice.
    Huang C; Shen S; Ma Q; Chen J; Gill A; Pollock CA; Chen XM
    Diabetes; 2013 Aug; 62(8):2923-34. PubMed ID: 23656889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of KCa3.1 suppresses TGF-β1 induced MCP-1 expression in human proximal tubular cells through Smad3, p38 and ERK1/2 signaling pathways.
    Huang C; Day ML; Poronnik P; Pollock CA; Chen XM
    Int J Biochem Cell Biol; 2014 Feb; 47():1-10. PubMed ID: 24291552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of KCa3.1: A novel target to treat TGF-β1 induced conjunctival fibrosis.
    Anumanthan G; Wilson PJ; Tripathi R; Hesemann NP; Mohan RR
    Exp Eye Res; 2018 Feb; 167():140-144. PubMed ID: 29242028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channel.
    Huang C; Pollock CA; Chen XM
    PLoS One; 2014; 9(4):e95173. PubMed ID: 24733189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KCa3.1 mediates dysfunction of tubular autophagy in diabetic kidneys via PI3k/Akt/mTOR signaling pathways.
    Huang C; Lin MZ; Cheng D; Braet F; Pollock CA; Chen XM
    Sci Rep; 2016 Mar; 6():23884. PubMed ID: 27029904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy.
    Huang C; Zhang L; Shi Y; Yi H; Zhao Y; Chen J; Pollock CA; Chen XM
    PLoS One; 2018; 13(2):e0192800. PubMed ID: 29425253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
    Anumanthan G; Gupta S; Fink MK; Hesemann NP; Bowles DK; McDaniel LM; Muhammad M; Mohan RR
    PLoS One; 2018; 13(3):e0192145. PubMed ID: 29554088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis.
    Xie H; Lu J; Zhu Y; Meng X; Wang R
    Toxicol Lett; 2018 Oct; 295():408-415. PubMed ID: 30036685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
    Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
    Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.
    Grgic I; Kiss E; Kaistha BP; Busch C; Kloss M; Sautter J; Müller A; Kaistha A; Schmidt C; Raman G; Wulff H; Strutz F; Gröne HJ; Köhler R; Hoyer J
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14518-23. PubMed ID: 19706538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gal-3 (Galectin-3) and K
    She G; Hou MC; Zhang Y; Zhang Y; Wang Y; Wang HF; Lai BC; Zhao WB; Du XJ; Deng XL
    Hypertension; 2020 Feb; 75(2):393-404. PubMed ID: 31838908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy.
    Loeffler I; Liebisch M; Allert S; Kunisch E; Kinne RW; Wolf G
    Cell Tissue Res; 2018 Apr; 372(1):115-133. PubMed ID: 29209813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of KCa3.1 Attenuates Left Ventricular Remodeling after Experimental Myocardial Infarction.
    Ju CH; Wang XP; Gao CY; Zhang SX; Ma XH; Liu C
    Cell Physiol Biochem; 2015; 36(4):1305-15. PubMed ID: 26160442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Klotho attenuates high glucose-induced fibronectin and cell hypertrophy via the ERK1/2-p38 kinase signaling pathway in renal interstitial fibroblasts.
    Huang JS; Chuang CT; Liu MH; Lin SH; Guh JY; Chuang LY
    Mol Cell Endocrinol; 2014 Jun; 390(1-2):45-53. PubMed ID: 24721634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway.
    Yu Z; Yu P; Chen H; Geller HM
    J Neurochem; 2014 Jul; 130(1):41-49. PubMed ID: 24606313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KCa3.1: a new player in progressive kidney disease.
    Huang C; Pollock CA; Chen XM
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):61-6. PubMed ID: 25415613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the potassium channel KCa3.1 in diabetic nephropathy.
    Huang C; Pollock CA; Chen XM
    Clin Sci (Lond); 2014 Oct; 127(7):423-33. PubMed ID: 24963668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol inhibits renal interstitial fibrosis in diabetic nephropathy by regulating AMPK/NOX4/ROS pathway.
    He T; Xiong J; Nie L; Yu Y; Guan X; Xu X; Xiao T; Yang K; Liu L; Zhang D; Huang Y; Zhang J; Wang J; Sharma K; Zhao J
    J Mol Med (Berl); 2016 Dec; 94(12):1359-1371. PubMed ID: 27488452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent.
    Roach KM; Wulff H; Feghali-Bostwick C; Amrani Y; Bradding P
    Respir Res; 2014 Dec; 15(1):155. PubMed ID: 25476248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.